新型含1,3,4-噁二唑的吡唑类化合物的合成及其抗肿瘤活性*
2014-08-30姚其正
王 京,张 磊,姚其正
(1.遵义医学院 药学院,贵州 遵义 563003;2.中国药科大学 药学院,江苏 南京 210009)
·研究论文·
新型含1,3,4-噁二唑的吡唑类化合物的合成及其抗肿瘤活性*
王 京1,张 磊1,姚其正2
(1.遵义医学院 药学院,贵州 遵义 563003;2.中国药科大学 药学院,江苏 南京 210009)
以4-甲氧基苯乙酮为原料,设计并合成了7个新型的含1,3,4-噁二唑的吡唑类化合物(7a~7g),其结构经1H NMR,IR和ESI-MS表征。并用MTT法测定了7a~7g抑制人肝癌细胞HepG2增殖的体外活性。结果表明,5-[3-(4-甲氧基苯基)-1-苯甲基吡唑-5-基]-2-[N-(4-溴苯基)乙酰胺-2-硫基]-1,3,4-噁二唑7g具有较好的抑制活性,其IC50为60.06μM。
吡唑;1,3,4-噁二唑;合成;抗肿瘤活性
吡唑是一类具有多种生物活性的母核结构,在生物医药领域具有重要的研究价值[1-2]。其中,3-苯基-1-芳香甲基吡唑衍生物是一类具有较强抗肿瘤活性的化合物,是国内外吡唑类杂环化合物研究的热点之一[3-5]。1,3,4-噁二唑类化合物是一种重要的有机杂环化合物,有广泛的生物活性,如抗细菌、抗病毒、抗真菌、抗肿瘤及酪氨酸激酶抑制剂等[6-8]。
根据基团拼合原理,将3-苯基-1-芳香甲基吡唑与1,3,4-噁二唑这两种抗肿瘤药效团骨架缀合,预期能筛选出高活性的抗肿瘤先导化合物。
为此,本文以4-甲氧基苯乙酮(1)为原料,设计并合成了7个新型的含1,3,4-噁二唑的吡唑类化合物(7a~7g,Scheme 1),其结构经1H NMR,IR和ESI-MS表征。并用MTT法测定了7a~7g抑制人肝癌细胞HepG2增殖的体外活性。
1 实验部分
1.1 仪器与试剂
Mel-TEMP型熔点仪(温度未校正);Bruck AV-300MHz型核磁共振仪(DMSO-d6为溶剂,TMS为内标);Nicolet Impact 410型红外光谱仪(KBr压片);HP1100LC/MSD型质谱仪;EL-x800型酶标仪。
2[9],3[3],4[10]和6a~6g[11]参考文献方法合成;其余所用试剂均为分析纯。
1.2 合成
(1)5的合成
在反应瓶中加入41.61g(5mmol)和氢氧化钾0.42g(7.5mmol)的乙醇(15mL)溶液,搅拌下于室温反应10min;于30min内缓慢滴加混合溶液[V(二硫化碳)∶V(乙醇)=0.6∶5]5.6mL;氮气保护下回流反应8h(TLC检测)。减压除溶,残余物用水溶解,过滤,滤液用10%盐酸调至pH 5~6,析出大量固体。抽滤,滤饼用乙醇重结晶得淡黄色固体5-[3-(4-甲氧基苯基)-1-苯甲基吡唑-5-基]-2-巯基-1,3,4-噁二唑(5)1.46g,收率80%,m.p.250℃~252℃;1H NMRδ: 3.78(s,3H,OCH3),5.71(s,2H,CH2Ph),6.97(d,J=8.6Hz,2H,ArH),7.20(d,J=7.5Hz,2H,ArH),7.27~7.36(m,3H,ArH),7.47(s,1H,ArH),7.82(d,J=8.5Hz,2H,ArH),14.75(br,1H,SH);IRν: 3091,2932,2831,2047,1955,1899,1608,1507,1463,1322,1051,1033,965cm-1;ESI-MSm/z: 365.2{[M+H]+}。
(2)7a~7g的合成(以7a为例)
向反应瓶中依次加入DMF 5mL,6a0.146g(0.72mmol),50.25g(0.68mmol),碳酸钾0.142g(1mmol)及碘化钾0.011g(0.068mmol),搅拌下于80℃反应2h。冷却至室温,加入适量水,搅拌至固体析出。抽滤,滤饼水洗三次,干燥后经硅胶柱层析[洗脱剂:V(乙酸乙酯)∶V(石油醚)=1∶5]纯化得5-[3-(4-甲氧基苯基)-1-苯甲基吡唑-5-基]-2-[N-(4-氯苯基)乙酰胺-2-硫基]-1,3,4-噁二唑(7a)321mg。
用类似的方法合成7b~7g。
7a:白色固体,收率89%,m.p.239℃~241℃;1H NMRδ: 3.78(s,3H,OCH3),4.19(s,2H,SCH2CO),5.69(s,2H,CH2Ph),6.98(t,J=8.6Hz,2H,ArH),7.18~7.33(m,6H,ArH),7.40(d,J=8.5Hz,2H,ArH),7.59(d,J=8.5Hz,2H,ArH),7.68(d,J=8.4Hz,2H,ArH),11.02(s,1H,NH);IRν: 3445,3179,2932,2560,2300,1896,1728,1616,1537,1487,1363,1298,1174,1089,953cm-1;ESI-MSm/z: 532.2{[M+H]+}。
7b:白色固体,收率90%,m.p.222℃~223℃;1H NMRδ: 3.78(s,3H,OCH3),4.19(s,2H,SCH2CO),5.71(s,2H,CH2Ph),6.98(d,J=8.5Hz,2H,ArH),7.19~7.36(m,9H,ArH),7.54~7.61(m,1H,ArH),7.68(d,J=8.3Hz,2H,ArH),11.03(s,1H,NH);IRν: 3451,3179,2938,2613,2289,1728,1649,1540,1437,1363,1248,1172,1021,956cm-1;ESI-MSm/z: 516.2{[M+H]+}。
7c:淡黄色固体,收率86%,m.p.250℃~251℃;1H NMRδ: 2.20(s,3H,CH3),3.77(s,3H,OCH3),4.17~4.35(m,2H,SCH2CO),5.70(s,2H,CH2Ph),6.98(d,J=8.6Hz,2H,ArH),7.18~7.34(m,7H,ArH),7.41(d,J=8.4Hz,1H,ArH),7.51(s,1H,ArH),7.67(d,J=8.5Hz,2H,ArH),11.01(s,1H,NH);IRν: 3557,3174,2938,2843,1731,1619,1513,1486,1364,1341,1204,1174,1089,956,897cm-1;ESI-MSm/z: 546.2{[M+H]+}。
7d:淡黄色固体,收率87%,m.p.256℃~258℃;1H NMRδ: 3.77(s,3H,OCH3),3.80(s,3H,OCH3),4.18(s,2H,SCH2CO),5.70(s,2H,CH2Ph),6.98(d,J=8.5Hz,2H,ArH),7.04(d,J=8.7Hz,2H,ArH),7.18~7.32(m,8H,ArH),7.68(d,J=8.4Hz,2H,ArH),10.97(s,1H,NH);IRν: 3433,3185,2967,2837,2554,2365,2041,1888,1725,1646,1504,1443,1337,1251,1174,1027,956,897cm-1;ESI-MSm/z: 528.2{[M+H]+}。
7e:白色固体,收率89%,m.p.241℃~242℃;1H NMRδ: 3.77(s,3H,OCH3),4.21~4.37(m,2H,SCH2CO),5.70(s,2H,CH2Ph),6.98(d,J=8.4Hz,2H,ArH),7.17~7.32(m,6H,ArH),7.58~7.70(m,4H,ArH),7.90(s,1H,ArH),11.04(s,1H,NH);IRν: 3433,3174,3067,2938,2837,1725,1649,1507,1450,1339,1301,1252,1175,1124,1030,956,877cm-1;ESI-MSm/z: 512.2{[M+H]+}。
7f:淡黄色固体,收率84%,m.p.181℃~183℃;1H NMRδ: 3.78(s,3H,OCH3),4.20(s,2H,SCH2CO),5.72(s,2H,CH2Ph),6.98(d,J=8.3Hz,2H,ArH),7.19~7.31(m,6H,ArH),7.69(d,J=8.2Hz,2H,ArH),7.82~7.92(m,2H,ArH),8.31~8.37(m,2H,ArH),11.19(s,1H,NH);IRν: 3634,3126,2943,2831,2359,1742,1657,1529,1438,1349,1247,1174,1089,959cm-1;ESI-MSm/z: 543.2{[M+H]+}。
7g:黄白色固体,收率89%,m.p.145℃~147℃;1H NMRδ: 3.78(s,3H,OCH3),4.19(s,2H,SCH2CO),5.70(s,2H,CH2Ph),6.98(d,J=8.7Hz,2H,ArH),7.18~7.37(m,8H,ArH),7.68~7.75(m,4H,ArH),11.02(s,1H,NH);IRν: 3439,3179,3067,2938,2831,1732,1651,1540,1486,1337,1298,1174,1095,1027,953cm-1;ESI-MSm/z: 576.1{[M+H]+}。
1.3 抗肿瘤活性
以5-Fu和紫杉醇为阳性对照药,采用MTT法测定7a~7g抑制人肝癌细胞HepG2增殖的体外活性。HepG2经消化和计数,配制为浓度3.5×104个·mL-1的细胞悬液,以3.5×103个·mL-1细胞密度接种于96孔细胞培养板,每孔100μL;于37℃,5%CO2培养箱中培养24h;用完全培养基稀释药物至所需浓度,每孔加入100μL含药培养基;相同条件下培养72h。将96孔板进行MTT(5mg·mL,每孔20μL)染色,继续培养4h。弃去培养基,每孔加入150μL DMSO,轻摇10min后测定490nm处各孔OD值并计算抑制率和半数抑制浓度(IC50)。
2 结果与讨论
2.1 合成
在合成2时,使用新制乙醇钠/乙醇溶液,1可顺利反应制得2。直接使用市售乙醇钠,2收率较低。使用新制的甲醇钠/甲醇体系,经1H NMR鉴定发现,2的乙酯基团将会转变成甲酯。
此外,2吡唑环上的NH存在互变异构现象。苄基取代后,3存在同分异构体3′(淡黄色油状物,收率26%,Chart 1),两者可通过柱层析分离。
表 1 7a~7g对HepG2的抑制活性Table 1 The inhibition activities of 7a~7g on HepG2
经1H NMR确认,3苄基上的亚甲基的化学位移值为5.8,与文献报道值一致[3];而3′苄基上的亚甲基的化学位移值则为5.5。
2.27a~7g的抗肿瘤活性
7a~7g对HepG2的抑制活性见表1。由表1可见,7a~7g均具有一定的抗肿瘤活性,其中7d,7e和7g的活性较强,IC50在60.06μM~69.52μM,但均较阳性对照药5-Fu和紫杉醇的抗肿瘤活性弱。
构效关系研究显示,末端苯环4-位有供电子取代基时,7的活性均较强,如7d和7e;但4-位取代基为溴时,7g的活性最强;末端苯环其它位置有取代基时,化合物的抗肿瘤活性均较弱。
3 结论
根据结构拼合原理,合成了7个新型的含1,3,4-噁二唑的吡唑类化合物(7a~7g)。用MTT法测定了7a~7g抑制人肝癌细胞HepG2增殖的体外活性。结果表明,7g具有较好的抑制活性,其IC50为60.06μM。
[1] Kumar H,Saini D,Jain S,etal.Pyrazole scaffold: A remarkable tool in the development of anticancer agents [J].Eur J Med Chem,2013,70:248-258
[2] Liu J J,Zhao M,Zhang X,etal.Pyrazole derivatives as antitumor,anti-inflammatory and antibacterial agents[J].Mini-Rev Med Chem,2013,13(13):1957-1966
[3] Ding X L,Meng N,Xia Y,etal.Synthesis and bioactivity evaluation of ethyl 1-arylmethyl-3-aryl-1H-pyrazole-5-carboxylate derivatives[J].Chin J Org Chem,2007,27(12):1542-1546
[4] Xia Y,Dong Z W,Zhao B X,etal.Synthesis and structure-activity relationships of novel 1-arylmethyl-3-aryl-1H-pyrazole-5-carbohydrazide derivatives as potential agents against A549lung cancer cells[J].Bioorg Med Chem,2007,15(22):6893-6899
[5] Xia Y,Fa C D,Zhao B X,etal.Synthesis and structure-activity relationships of novel 1-arylmethyl-3-aryl-1H-pyrazole-5-carbohydrazide hydrazine derivatives as potential agents against A549lung cancer cells[J].Eur J Med Chem,2008,43(11):2347-2353
[6] Gaonkar S L,Rai K M,Prabhuswamy B.Synthesis and antimicrobial studies of a new series of 2-{4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}-5-substituted-1,3,4-oxadiazoles[J].Eur J Med Chem,2006,41(7):841-846
[7] de Oliveira C S,Lira B F,Barbosa Filho J M,etal.Synthetic approaches and pharmacological activity of 1,3,4-oxadiazoles:A review of the literature from 2000~2012[J].Molecules,2012,17(9):10192-10231
[8] Maccioni E,Alcaro S,Cirilli R,etal.3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles:A new scaffold for the selective inhibition of monxoamine oxidase B[J].J Med Chem,2011,54(18):6394-6398
[9] Crane J D,Fox O D,Sinn E.Synthesis and structural characterisation of the isotypic complexes MIIL2(py)2·2H2O(M=Cu,Zn);the interplay of lattice imposed ligand disposition and Jahn-Teller distortions [HL=5-(4-methoxyphe-nyl)pyrazole-3-carbo-xylic acid][J].J Chem Soc,1999,9:1461-1466
[10] Xia Y,Dong Z W,Zhao B X,etal.Synthesis and structure-activity relationships of novel 1-arylmethyl-3-aryl-1H-pyrazole-5-carbohydrazide derivatives as potential agents against A549lung cancer cells[J].Bioorg Med Chem,2007,15(22):6893-6899
[11] Singh D C P,Hashim S R,Singhal.Synthesis and antimicrobial activity of some new thioether derivatives of quinoxaline[J].E-Journal of Chemistry,2011,8(2):635-642.
SynthesisandAnti-tumorActivitiesofNovelPyrazoleDerivativesContaining1,3,4-Oxadiazole
WANG Jing1,ZHANG Lei1,YAO Qi-zheng2
(1.School of Pharmacy,Zunyi Medical College,Zunyi 563003,China;2.School of Pharmacy,China Pharmaceutical University,Nanjing 210009,China)
Seven novel pyrazole derivatives(7a~7g)containing 1,3,4-oxadiazole were designed and synthesized from 4-methoxyacetophenone.The structures were characterized by1H NMR,IR and ESI-MS.Theinvitroanti-tumor activities of7a~7gwere investigated by MTT method.The results showed that 5-[3-(4-methoxyphenyl)-1-benzylpyrazole-5-yl]-2-[N-(4-bromophenyl)acetamide-2-ylthio]-1,3,4-oxadiazole(7g)exhibited good inhibition activities against HepG2with IC50of 60.06μM.
pyrazole;1,3,4-oxadiazole;synthesis;anti-tumor activity
2014-05-24
贵州省教育厅资助项目{黔科合人才团队字[2012]03号};贵州省科技厅资助项目{黔科合人才团队[2014]4002号};遵义医学院博士启动资金资助项目(F-631,zmk2013-008)
王京(1988-),女,汉族,贵州遵义人,讲师,主要从事新药分子的设计与合成研究。E-mail: wangjing0642320@126.com
张磊,副教授,E-mail:lei_chang@yeah.net
O626.21;O626.24
A
1005-1511(2014)06-0730-04